Correlation of Visible-Residue Limits with Swab Results for Cleaning Validation - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Correlation of Visible-Residue Limits with Swab Results for Cleaning Validation

Pharmaceutical Technology

Table III: Residual development formulation (μg/swab).
The cleaning procedures used the appropriate cleaning standard operating procedure to verify the repeatability of the cleaning processes to control residue. In addition, during one of the three validation trials for each piece of equipment, a seven-day "dirty" hold time established the longest allowable time between the completion of the filling and packaging process and the start of the subsequent cleaning process.

The acceptable API limit for the clinical packaging equipment was 100 μg/swab (25 cm2 ). This limit was based on adulteration of the subsequent batch of packaged material. The adulteration limit was used exclusively because any material with a potential safety concern is packaged in an isolated facility and equipment cleaning is addressed on a case-by-case basis. In addition, product contact with the equipment was limited in this case compared with manufacturing equipment because the formulation was in final market image.

Investigation. The investigation into the VRL and swab numbers for metformin targeted the assay method, the cleaning method, and the VRL determination of the API and formulation. The swab samples' testing was by HPLC and the assay run was reviewed as well as the method validation data. The cleaning process used in the clinical packaging area was reviewed for potential chemical interactions. The VRL determination of metformin was investigated for potential issues.

Results and discussion

Cleaning validation. A cleaning-validation study was completed successfully in a clinical packaging facility. The study used the worst-case packaging situations and all swab samples assayed below the ARL of 100 μg/swab (see Tables II and III) for the three executions (including 7-day idle time before cleaning). The cleaning processes used in the clinical packaging area are considered validated for hold times as long as 7 days.

The only problem was the discrepancy between the swab results for metformin and the VRL. The VRL data indicated that anything greater than 25 μg/swab should have been detected visually. A visual inspection of the equipment before sample swabbing concluded that it was visually clean.

Investigation. The investigation into the discrepancy between the metformin VRL and swab data began with the HPLC assay of the samples. Nothing was consistently present in the samples to suggest contamination of the swabs or solvents because the majority of the samples (58 of 69) had assay values below the VRL (see Figures 1a, 2a). Nothing in the sample chromatograms indicated the presence of an intermittent extraneous peak, which might explain the high results. The chromatogram of a control containing a swab, swabbing solvent, and extraction solvent showed no peaks. The system suitability data were within testing parameters. The HPLC assay did not indicate a potential cause.

The method-validation data and documentation review indicated that all validation parameters were within accepted guidelines, including recoveries from stainless steel coupons. Forced degradation studies of metformin showed no degradate peaks to explain the observed swab results.

The cleaning process for equipment in the clinical packaging area consisted of an appropriate amount of equipment disassembly such that all surfaces were accessible. A dry vacuum removed most residue from the equipment. The equipment surfaces were cleaned with an appropriate solvent and then dried before reassembly. A sample of metformin prepared in the cleaning solvent showed no evidence of degradation.

Table IV: Metformin visible residue limit recovery study.
A review of the VRL determination for metformin noted that the VRL samples were dried under nitrogen to prevent potential oxidation of the material, which had been noted on a previous compound. The VRL study was repeated using API and formulation dispersed in alcohol, but the samples were air dried rather than under nitrogen to simulate drying conditions in the packaging area. Sample concentrations were at the VRL of 25 μg/swab level and at the approximate level of the highest sample obtained during the validation studies, 75 μg/swab. Spots were applied in triplicate to 3 6-in. stainless steel coupons.

Figure 1
A visual examination of the metformin residues confirmed that the 25-μg/swab spots were visible. The 75-μg/swab spots exhibited a proportionally greater amount of visible residue. The metformin residues were swabbed and assayed by HPLC. The swab results from the formulation (see Table IV) matched the nominal residue amounts. Nonetheless, several swab results for the 25-and 75-μg API spots were significantly higher. As with the HPLC assays for the cleaning validation samples from the packaging area, no contaminants or extraneous peaks were present to explain the intermittent high results.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here